We are pleased to announce that Biocytogen will be attending PBSS Organoids and Tissue Bioengineering: on October 20th in Foster City, CA! Have the opportunity to listen in on Professional speakers, as well as gain knowledge and a deeper understanding of Organoids and the methods behind tissue bioengineering. Stop by our vendor to meet the team,learn more about Biocytogen and how we are striving to make an impact on developments in the biotech industry. We hope to see you in Foster City!
What is the PBSS Organoids and Tissue Bioengineering?
The PBSS Organoids and Tissue Bioengineering Workshop is a full-day experience, offering a well-structured curriculum that spans foundational concepts, recent advances, real-world applications, and case studies on the topic of Organoids and Tissue Bioengineering. Hear from expert speakers with coordinated presentations that bring insight to the life sciences field.
With the recent FDA memo on phasing out preclinical animal testing requirements for certain drugs and promoting the use of New Approach Methodologies (NAMs), the shift in broader strategy has brought new technologies to the forefront. This symposium covers a broad spectrum of NAMs, including organ-on-a-chip and AI/ML computation modeling, to reduce traditional animal studies in pharmacological safety and efficacy assessments. These future technologies and discoveries are essential to faster drug development and deeper understanding of human disease, ultimately resulting in better and safer novel treatments.
Event Overview
Date: October 20th | 8:45 am-5:30pm PT
Venue: Crowne Plaza Hotel. 1221 Chess Dr, Foster City, CA 94404
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the PBSS Organoids and Tissue Bioengineering in Foster City!
